Diabetes without Manifest Cardiovascular Disease: A Novel Approach in Risk Stratification and Treatment Selection.

Autor:	Andari E; Division of Endocrinology, Department of Internal Medicine, Notre Dame Des Secours, Beirut, Lebanon., Arnaout S; Division of Cardiology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon., Azar ST; Division of Endocrinology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon., Chammas E; Division of Cardiology, Department of Internal Medicine, Clemenceau Medical Center, Beirut, Lebanon., Jambart S; Division of Endocrinology, Department of Internal Medicine Hotel Dieu De France, Beirut, Lebanon., Saleh M; Division of Endocrinology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon., Nemr R; Division of Endocrinology, Department of Internal Medicine, Lebanese American University Medical Center - Rizk Hospital, Beirut, Lebanon., Sarkis A; Division of Cardiology, Department of Internal Medicine Hotel Dieu De France, Beirut, Lebanon.
Jazyk:	angličtina
Zdroj:	Current diabetes reviews [Curr Diabetes Rev] 2020; Vol. 16 (8), pp. 869-873.
DOI:	10.2174/1573399816666200120122929
Abstrakt:	Background: Cardiovascular disease (CVD), the main macro vascular complication of type 2 diabetes (T2D), increases the risk of death significantly in patients with T2D. Introduction: Most of the patients with T2D do not have obvious CVD symptoms. Due to the paucity of data, CVD screening in asymptomatic patients with T2D remains highly controversial. Methods: This has driven a panel of experts to establish a novel consensus on how to approach patients with T2D at high CVD risk. The panel formulated a stepwise algorithm by which patients with T2D undergo initial risk stratification into low, intermediate and high risk using the ASCVD calculator. In patients with intermediate risk, coronary artery calcium measurement is used to further stratify those patients into new low and high-risk categories. Results and Conclusion: The panel recommends using standard diabetes care in low risk patients and using SGLT2 inhibitors and GLP1 agonists with cardio protective effect, on top of standard care, in high risk individuals. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu